Suchen Sie hier direkt nach Handelsname oder Wirkstoff des benötigten Arzneimittels:
Named Patient Imports
Health is at the centre of our work and each individual case is crucial.
We therefore process all enquiries or orders with our full dedication, expertise and experience:
For more than 20 years, we have been making the world's innovations available in Germany before they are authorised, or we have been closing supply gaps in the event of supply bottlenecks or in the case of medicinal products that are not (or no longer) authorised nationally - within the framework of Named Patient Imports in accordance with Section 73 (3) of the German Medicinal Products Act (AMG).
PHARMORE GmbH acts as a service provider for pharmacies. Named Patient Imports are supplied exclusively to hospital pharmacies or community pharmacies.
We offer our customers PHARMORE:
Fast
If we receive a pharmacy's order by 4 p.m. on any business day, we will generally deliver medications on the next business day, provided we have them in stock.
Global
If we don’t have a drug in stock, we will obtain it for our customers – wherever it’s available around the globe: our global network means we can offer patients in Germany access to medications from anywhere in the world.
Customs warehouse
As one of the leading suppliers of Named Patient Imports, we keep many of the permanently needed Named Patient Imports on stock in our customs warehouse.
Experience
Our customers benefit from our more than 20 years of experience as one of the leading specialist providers of professional Named Patient Imports in accordance with Section 73 (3) AMG – quality always shows!
Reliable
We stand for reliability, quality and transparency. We’re also the specialist when it comes to legal requirements.
24/7 emergency hotline
PHARMORE has a specially trained emergency management team available to assist in emergencies.
Named Patient Import according to Section 73 (3) AMG: in which cases?
This link will take you to the current version of the Medicinal Products Act on the Federal Ministry of Justice's website.
Innovations
Novel, innovative and therapeutically significant drug therapies
(e. g. from the USA) can be procured from abroad for certain individual cases even before they are authorised in Germany.
Supply bottlenecks
Temporary supply gaps caused by supply bottlenecks can be closed.
Cessation of distribution
Long-established medicinal products that are not or are no longer distributed nationally, particularly for economic reasons, can be procured under certain conditions.
What needs to be considered?
The following applies in principle to the order of a Named Patient Import according to Section 73 (3) AMG:
- Ordering is only possible through pharmacies.
- By order of a single person.*
- In small quantities.*
- Dispensing within the scope of the existing pharmacy operating licence.
*Exception see "Import facilitation for hospital pharmacies"
Additionally the following applies to the medicine (to be procured) itself:
Marketability in the state of origin:
The medicinal product may be legally placed on the market in the state from which it is imported into Germany.
Supply gap:
There are no medicinal products available in Germany for the therapeutic indication in question, which are identical in terms of the active substance and comparable in terms of the strength.
IMPORTANT:
The import and distribution of medicinal products for doping purposes (Section 2 Anti-Doping Law), as well as of unsafe medicinal products (Section 5 AMG) and expired medicinal products (Section 8 AMG) is prohibited – without restriction even in the case of Named Patient Imports.
SPECIAL: Import facilitation for hospital pharmacies
Especially for hospital pharmacies and pharmacies supplying hospitals, the legislator has provided import facilitation under the condition of marketability in the state of origin and an existing supply gap.
This means that, in the event of supply bottlenecks, there is the option of temporarily stocking up on Named Patient Imports
- to an appropiate quantity,
- to ensure proper treatment of the hospital's patients.
Good to know: "Not all imports are the same" – But what are the differences?
Parallel import
Pharmaceutical manufacturers generally market their products in many countries. Medicines are referred to as parallel-imported drugs if, for example, a third company acquires them in another EU member state and imports them into Germany in order to market them there as well - in parallel with the original pharmaceutical entrepreneur. Parallel-imported medicines have a marketing authorisation in Germany.
Re-import
Similar is the case of re-imports, but with the difference that these drugs were previously manufactured in Germany and exported to other countries. Re-imported finished drugs are also drugs that have authorisation in Germany.
Named Patient Import according to Section 73 (3) AMG
Through a Named Patient Import according to Section 73 (3) AMG, medicinal products which are not (yet) or no longer available in Germany can be procured under certain conditions. This concerns the import of medicines that are not authorised in Germany and their further distribution.